Navigation Links
SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business
Date:7/7/2009

CEO of SecureWorks. "Today, the Internet threats being levied at organizations and their customers are increasing in both volume and complexity and, unfortunately, the threats are growing for all sizes of organizations. A security services provider that has knowledge and expertise, a broad client base providing data, a robust infrastructure, and a trusted reputation meets a critical need for organizations in today's business and computing environment. With this acquisition, SecureWorks solidifies its position as one of the market's top security services providers and, indeed, one of the largest pure-play providers serving the entire market."

"The sale of the Managed Security Services business is another important step toward VeriSign's divestiture goals as we continue our focus on core Internet infrastructure businesses," said Jim Bidzos, executive chairman of the board of directors and chief executive officer on an interim basis of VeriSign. "Our primary objective throughout the MSS divestiture process was to work with a buyer who is a recognized leader in the field - one that could facilitate a smooth transition for customers and present the most promising opportunities for our employees. With SecureWorks, we believe we achieved this objective."

Post-closing, SecureWorks employs approximately 500 people globally and anticipates run-rate revenues greater than $100 million annually.

SecureWorks Security Services

SecureWorks provides a broad array of integrated security services including: management of Intrusion Detection and Prevention Systems, Network and Web Application Firewalls, 24x7 Security Monitoring, Security Information and Event Management (SIEM), Log Management, Threat Research, Vulnerability Management, 3rd Party Risk Management, Risk Assessments, Compliance Audits, Governance and Policy Development, Incident Response and Expert Residency.

About SecureWo
'/>"/>

SOURCE SecureWorks, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. SecureWorks, Inc. Wins SC Magazines Reader Trust Award for Best Managed Security Service for Four Years Running
2. SecureWorks, Inc. Launches Managed Web Application Firewall Service
3. SecureWorks Partners With ETEK International to Provide Security Services to the South American and Latin American Markets
4. Major Retailers Experience 161% Increase in Attempted Hacker Attacks, According to SecureWorks
5. SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2
6. Compromised US and Chinese Computers Launch Greatest Number of Cyber Attacks, According to SecureWorks Data
7. SecureWorks Revolutionizes Security Information Management With New, On-Demand Service
8. SecureWorks Designated as a Qualified Security Assessor for PCI Audits
9. SecureWorks Ranked 6th in Deloittes Technology Fast 50 Program for Georgia
10. BioMed Realty Trust Closes New $18 Million Secured Loan
11. I-Therapeutix, Inc. Closes $15 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 3Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 4Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 5Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 6